CNS trades 16.6% below Wall Street's consensus target of $88.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CNS achieves its forward estimates and maintains a stable P/E multiple of 21.6x. This scenario reflects the blended consensus of 13 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Cohen & Steers, Inc. (CNS) has a Wall Street consensus price target of $88.00, based on estimates from 13 covering analysts. With the stock currently trading at $75.44, this represents a potential upside of +16.6%. The company has a market capitalization of $3.88B.
Analyst price targets range from a low of $88.00 to a high of $88.00, representing a 0% spread in expectations. The median target of $88.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Sell, with 4 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 5 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, CNS trades at a trailing P/E of 25.3x and forward P/E of 21.6x. The forward PEG ratio of 1.58 indicates reasonable valuation for growth. Analysts expect EPS to grow +15.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $82.15, with bear and bull scenarios of $51.75 and $108.24 respectively. Model confidence stands at 42/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 VRTSVirtus Investment Partners, Inc. | $855M | $128.00 | $145.00 | +13.3% | Hold | 5.4x | 11 |
 VCTRVictory Capital Holdings, Inc. | $6.6B | $106.31 | $111.00 | +4.4% | Hold | 13.4x | 13 |
 DHILDiamond Hill Investment Group, Inc. | $473M | $174.99 | — | — | — | 9.5x | — |
 GROWU.S. Global Investors, Inc. | $38M | $2.97 | — | — | — | — | — |
 HNNAHennessy Advisors, Inc. | $82M | $10.37 | — | — | — | — | — |
 BENFranklin Resources, Inc. | $17.0B | $32.71 | $34.60 | +5.8% | Hold | 11.3x | 27 |
 IVZInvesco Ltd. | $13.6B | $30.74 | $32.80 | +6.7% | Hold | 10.9x | 28 |
 AMGAffiliated Managers Group, Inc. | $9.7B | $366.17 | $410.00 | +12.0% | Buy | 9.9x | 12 |
 APAMArtisan Partners Asset Management Inc. | $2.5B | $35.62 | $40.00 | +12.3% | Hold | 9.2x | 15 |
 MORNMorningstar, Inc. | $7.5B | $200.32 | $227.33 | +13.5% | Hold | 16.3x | 6 |
Quick answers to the most common questions about buying CNS stock.
Cohen & Steers, Inc. (CNS) has a consensus 12-month price target of $88, implying 16.6% upside from $75.44. The 13 analysts covering CNS see moderate appreciation potential.
CNS has a consensus rating of "Sell" based on 13 Wall Street analysts. The rating breakdown is leaning bearish, with 5 Sell/Strong Sell ratings. The consensus 12-month price target of $88 implies 16.6% upside from current levels.
CNS trades at a forward P/E of 21.6471x, representing a moderate valuation. With analysts targeting $88 (16.6% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $88 for CNS, while the most conservative target is $88. The consensus of $88 represents the median expectation. Our quantitative valuation model projects a bull case target of $108 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CNS is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 5 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CNS stock forecast based on 13 Wall Street analysts shows a consensus price target of $88, with estimates ranging from $88 (bear case) to $88 (bull case). The median consensus rating is "Sell". Our proprietary valuation model produces a base case fair value of $82, with bear/bull scenarios of $52/$108.
Our quantitative valuation model calculates CNS's fair value at $82 (base case), with a bear case of $52 and bull case of $108. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 42/100.
CNS trades at a forward P/E ratio of 21.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 25.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on CNS, with a "Sell" consensus rating and $88 price target (16.6% upside). 4 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CNS analyst price targets range from $88 to $88, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $88 consensus represents the middle ground. Our model's $52-$108 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.